Integral Diagnostics Limited
Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company offers magnetic resonance imaging, positron emission tomography, computed tomography mammography, interventional radiology, ultrasound, and radiography, such as … Read more
Integral Diagnostics Limited (ITGDF) - Net Assets
Latest net assets as of June 2025: $693.94 Million USD
Based on the latest financial reports, Integral Diagnostics Limited (ITGDF) has net assets worth $693.94 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.43 Billion) and total liabilities ($732.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $693.94 Million |
| % of Total Assets | 48.65% |
| Annual Growth Rate | 32.67% |
| 5-Year Change | 172.41% |
| 10-Year Change | N/A |
| Growth Volatility | 50.05 |
Integral Diagnostics Limited - Net Assets Trend (2019–2025)
This chart illustrates how Integral Diagnostics Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Integral Diagnostics Limited (2019–2025)
The table below shows the annual net assets of Integral Diagnostics Limited from 2019 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $693.94 Million | +130.01% |
| 2024-06-30 | $301.71 Million | -19.12% |
| 2023-06-30 | $373.05 Million | +7.43% |
| 2022-06-30 | $347.24 Million | +36.31% |
| 2021-06-30 | $254.74 Million | +11.57% |
| 2020-06-30 | $228.33 Million | +79.48% |
| 2019-06-30 | $127.22 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integral Diagnostics Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 229.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $730.13 Million | 105.36% |
| Total Equity | $693.00 Million | 100.00% |
Integral Diagnostics Limited Competitors by Market Cap
The table below lists competitors of Integral Diagnostics Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Citizens & Northern Corp
NASDAQ:CZNC
|
$372.96 Million |
|
Shanghai New World Co Ltd
SHG:600628
|
$373.06 Million |
|
Renew Energy Global PLC
NASDAQ:RNW
|
$373.20 Million |
|
Jiangxi Xinyu Guoke Technology Co Ltd Class A
SHE:300722
|
$373.24 Million |
|
COM.HEALTHC.TR.INC.DL-01
F:4U9
|
$372.92 Million |
|
SPIN MASTER
F:SP9
|
$372.90 Million |
|
TOTAL ENERGY SERVS INC.
F:5O7
|
$372.90 Million |
|
Zhonglu Co Ltd A
SHG:600818
|
$372.86 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integral Diagnostics Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 301,707,000 to 693,000,000, a change of 391,293,000 (129.7%).
- Net income of 4,673,000 contributed positively to equity growth.
- Dividend payments of 15,457,000 reduced retained earnings.
- Other factors increased equity by 402,077,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $4.67 Million | +0.67% |
| Dividends Paid | $15.46 Million | -2.23% |
| Other Changes | $402.08 Million | +58.02% |
| Total Change | $- | 129.69% |
Book Value vs Market Value Analysis
This analysis compares Integral Diagnostics Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.13x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.68x to 1.13x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-06-30 | $0.78 | $2.10 | x |
| 2020-06-30 | $1.16 | $2.10 | x |
| 2021-06-30 | $1.26 | $2.10 | x |
| 2022-06-30 | $1.52 | $2.10 | x |
| 2023-06-30 | $1.60 | $2.10 | x |
| 2024-06-30 | $1.29 | $2.10 | x |
| 2025-06-30 | $1.86 | $2.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integral Diagnostics Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.67%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.75%
- • Asset Turnover: 0.44x
- • Equity Multiplier: 2.06x
- Recent ROE (0.67%) is below the historical average (4.33%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 16.49% | 9.08% | 0.73x | 2.47x | $8.26 Million |
| 2020 | 10.09% | 8.40% | 0.47x | 2.54x | $200.00K |
| 2021 | 12.27% | 8.96% | 0.53x | 2.57x | $5.79 Million |
| 2022 | 4.21% | 4.07% | 0.46x | 2.25x | $-20.12 Million |
| 2023 | 6.71% | 5.69% | 0.52x | 2.25x | $-12.26 Million |
| 2024 | -20.12% | -12.92% | 0.63x | 2.47x | $-90.87 Million |
| 2025 | 0.67% | 0.75% | 0.44x | 2.06x | $-64.63 Million |
Industry Comparison
This section compares Integral Diagnostics Limited's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $914,015,556
- Average return on equity (ROE) among peers: -22.24%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integral Diagnostics Limited (ITGDF) | $693.94 Million | 16.49% | 1.06x | $372.93 Million |
| Agilent Technologies Inc (A) | $4.08 Billion | 3.46% | 0.65x | $31.80 Billion |
| Amer Bio Medica (ABMC) | $3.38 Million | -26.64% | 1.08x | $3.55K |
| ADCNF (ADCNF) | $1.77 Billion | 2.65% | 1.64x | $172.01 Million |
| Advanced Biomed Inc. Common Stock (ADVB) | $3.48 Billion | 0.00% | 0.87x | $1.68 Million |
| ANGLE plc (ANPCF) | $18.44 Million | -77.14% | 0.38x | $34.42 Million |
| SeqLL Inc. (ATLN) | $8.18 Million | -45.26% | 0.31x | $35.63K |
| Avricore Health Inc (AVCRF) | $2.20 Million | -79.50% | 0.04x | $3.22 Million |
| Aspira Womens Health Inc (AWH) | $-11.46 Million | 0.00% | 0.00x | $664.47K |
| Biodesix Inc (BDSX) | $-198.03 Million | 0.00% | 0.00x | $50.38 Million |
| bioAffinity Technologies, Inc. (BIAF) | $-15.79 Million | 0.00% | 0.00x | $5.08 Million |